The related transcriptional enhancer factor-1 isoform, TEAD4 216, can repress vascular endothelial growth factor expression in mammalian cells by Appukuttan, Binoy et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Archived at the Flinders Academic Commons: 
http://dspace.flinders.edu.au/dspace/ 
This is the published version of this article. 
The original is available at: 
http://www.plosone.org/article/info:doi/10.1371/journal.p
one.0031260 
Please cite this as: Appukuttan, B., McFarland, T.J., Stempel, 
A., Kassem, J.B., Hartzell, M., Zhang, Y., Bond, D., West, K., 
Wilson, R., Stout, A., Pan, Y., Ilias, H., Robertson, K., Klein, 
M. L., Wilson, D., Smith, J.R. and Stout, J.T., 2012. The 
related transcriptional enhancer factor-1 Isoform, TEAD4 
216, can repress vascular endothelial growth factor 
expression in mammalian cells. PLoS One, 7(6), e31260. 
doi:10.1371/journal.pone.0031260 
© 2012 Appukuttan et al.  
This is an open-access article distributed under the terms of 
the Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any 
medium, provided the original author and source are 
credited. 
The Related Transcriptional Enhancer Factor-1 Isoform,
TEAD4216, Can Repress Vascular Endothelial Growth
Factor Expression in Mammalian Cells
Binoy Appukuttan*, Trevor J. McFarland, Andrew Stempel, Jean B. Kassem, Matthew Hartzell, Yi Zhang,
Derek Bond, Kelsey West, Reid Wilson, Andrew Stout, Yuzhen Pan, Hoda Ilias, Kathryn Robertson,
Michael L. Klein, David Wilson, Justine R. Smith, J. Timothy Stout
Casey Eye Institute, Oregon Health and Science University, Portland, Oregon, United States of America
Abstract
Increased cellular production of vascular endothelial growth factor (VEGF) is responsible for the development and
progression of multiple cancers and other neovascular conditions, and therapies targeting post-translational VEGF products
are used in the treatment of these diseases. Development of methods to control and modify the transcription of the VEGF
gene is an alternative approach that may have therapeutic potential. We have previously shown that isoforms of the
transcriptional enhancer factor 1-related (TEAD4) protein can enhance the production of VEGF. In this study we describe a
new TEAD4 isoform, TEAD4216, which represses VEGF promoter activity. The TEAD4216 isoform inhibits human VEGF
promoter activity and does not require the presence of the hypoxia responsive element (HRE), which is the sequence critical
to hypoxia inducible factor (HIF)-mediated effects. The TEAD4216 protein is localized to the cytoplasm, whereas the
enhancer isoforms are found within the nucleus. The TEAD4216 isoform can competitively repress the stimulatory activity of
the TEAD4434 and TEAD4148 enhancers. Synthesis of the native VEGF165 protein and cellular proliferation is suppressed by
the TEAD4216 isoform. Mutational analysis indicates that nuclear or cytoplasmic localization of any isoform determines
whether it acts as an enhancer or repressor, respectively. The TEAD4216 isoform appears to inhibit VEGF production
independently of the HRE required activity by HIF, suggesting that this alternatively spliced isoform of TEAD4 may provide a
novel approach to treat VEGF-dependent diseases.
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Introduction
Alternate splicing to generate multiple mRNAs and subsequent
protein products from one gene is exploited in many organisms,
and in different tissues within the same organism, to augment the
functional complexity of the translated genome. [1–3] Transcrip-
tional enhancer factor 1 (TEF-1) is a member of the TEA DNA-
binding family (TEAD), in which tissue and disease specific
isoforms, generated by alternate splicing, have been observed.
[4,5] The TEAD family of proteins is remarkably conserved from
yeast to humans and, depending upon interaction with other
proteins, can either activate or repress gene expression. [6] Four
TEAD genes exist in mammals (TEAD 1 to 4) and expression of
these genes has been characterized in various mammalian tissues
and cell types.[7–9] Transcriptional enhancer factor 1-related
(RTEF-1 or TEAD4) protein was originally reported to regulate
muscle-specific genes in cardiac and smooth muscle cells. [8] The
TEAD4 transcription factor requires the presence of myocyte-
specific (M-CAT) sequences and muscle-specific cofactors to
facilitate cell-specific gene regulation. Human and mouse TEAD4
transcripts exhibit dissimilar tissue specific expression profiles,
where highest expression in humans is observed in pancreas and
skeletal muscle with low levels in heart and kidney, whereas
murine lung tissue has the most abundant message with low levels
in heart and skeletal muscle. [7,10] The mouse embryo expresses
high levels of TEAD4 message within skeletal muscle as well as an
alternatively spliced isoform that lacks exon 5 relative to the full-
length gene, indicating that within the mouse, TEAD4 is regulated
developmentally and at least one isoform exists. [10] Alternative
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splicing of TEAD4 in human cells and regulation of non-muscle
specific genes is less well characterized.
Recently, alternatively spliced transcripts for TEAD4 have been
identified in human retinal vascular endothelial cells. [11] Shie
and colleagues showed that full length TEAD4 protein was able to
bind to Sp1 sequences within the VEGF promoter and enhance
VEGF gene expression in bovine aortic endothelial cells. [12]
TEAD4 expression was up-regulated under hypoxic conditions,
and TEAD4 mediated stimulation of VEGF expression was
independent of the classic hypoxia responsive element (HRE) and
hypoxia-inducible factor (HIF-1) mechanism. [12] We identified
two new human isoforms, 936 (TEAD4311) and 447 (TEAD4148),
which enhanced VEGF promoter activity. The TEAD4148 isoform
was the most potent enhancer relative to other isoforms.
Interestingly, the TEAD4148 isoform was identified in human
ocular endothelial cells cultured under hypoxic conditions,
suggesting that environment-specific alternate splicing may occur
within human tissue to generate specific transcription factors with
altered functions. In this study, we report an alternatively spliced
TEAD4 transcript that generates a novel isoform (TEAD4216) able
to significantly repress promoter activity. This novel protein
reduces native VEGF production and cell proliferation. We show
that the TEAD4216 isoform can function in the absence of the
HRE sequence and overcomes the enhancement mediated by the
other TEAD4 isoforms. In addition we demonstrate the presence
of TEAD4 protein in choroidal neovascular membrane in human
age-related macular degeneration, suggesting a role in human
disease.
Results
Sequence Comparison of TEAD4216 to Other TEAD4
Isoforms
Amplification from cDNA prepared from pooled total RNA
isolated from primary cultures of human choroidal (PCVEC),
retinal (PRVEC) and iris (PIVEC) vascular endothelial cells, with
primers to full length TEAD4, detected the previously described
TEAD4434 and TEAD4311 isoforms as well as a novel 651 bp
product (Figure S1A). Amplification of specific isoforms not only
varied between REC, CEC and IEC, but also differed under
hypoxic conditions (Figure S1B). The 651 bp product was
consistently amplified in all donors and ECs tested in this study.
In addition, TEAD434 and other isoforms were detected by
western blot analysis of primate retinal-choroidal endothelial cells
(Figure S2). The 651 bp (TEAD4216) isoform is generated by an
inframe splice event within exons 3 and 10 that results in loss of
the 39 end of exon 3, complete deletion of exons 4 to 9, and
absence of the 59 end of exon 10 (Figure 1). The donor splice site
occurs at the junction of Thr-92 and Arg-93, removing the last five
codons of exon 3, and the acceptor site occurs between Gly-310
Figure 1. Schematic diagram of the full length TEAD4 (TEAD4434) and the novel TEAD4216 isoform. The previously identified TEAD4148
isoform is also shown for comparison. Schematic indicates the TEA DNA-binding domain (TEAD), a putative nuclear localization signal (NLS), a proline
rich domain (PRD) and serine-threonine-tyrosine (STY) domains.
doi:10.1371/journal.pone.0031260.g001
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and Ser-311, eliminating the first eleven codons of exon 10. The
splicing event results in removal of the third alpha helix and a
nuclear localization signal (NLS), within the TEA DNA-binding
domain, the proline rich domain (PRD) and a hydroxyl containing
amino acid rich STY domain (Figure 1). The combination of
specific protein motifs present in the TEAD4216 isoform is novel
when compared with the previously identified TEAD4311 and
TEAD4148 isoforms. [11].
The TEAD4216 Isoform Represses VEGF Promoter Activity
The full-length TEAD4 isoform (TEAD4434) acts as a
transcriptional enhancer of VEGF in bovine aortic endothelial
cells. [12] Reporter assays indicate that the TEAD4311 and
TEAD4148 isoforms increase human VEGF promoter activity.
[11] To test whether the TEAD4216 isoform was able to effect
VEGF promoter-driven transcription, co-transfection experiments
in 293T cells with a reporter plasmid that placed the secretable
alkaline phosphatase (SEAP) gene under the transcriptional
control of the VEGF promoter (1,136 bp of the 59 proximal
VEGF promoter and 54 bp of the VEGF gene 59UTR), and an
expression plasmid containing the TEAD4216 cDNA, were
performed. The TEAD4216 isoform repressed VEGF promoter
activity approximately 50% below background (P,0.05, Figure 2).
The TEAD4216 Isoform Does not Require the HRE
Sequence to Repress VEGF Promoter Activity
The hypoxia-inducible factor (HIF)-1 subunits require the
presence of a specific sequence the HRE, situated between –985
and –939 bp within the human VEGF 59 promoter to function as
an enhancer of transcription. The HIF-1 induced VEGF
expression is initiated under conditions of cellular oxygen
starvation as observed in tumor tissue and ischemic disease.[13–
16] Full-length human TEAD4 (TEAD4434) stimulates VEGF
production independent of the HIF-1/HRE pathway in bovine
endothelial cells. [12] To assess whether the TEAD4216 isoform
requires the HRE sequence to repress VEGF activity, a reporter
plasmid containing a truncated promoter fragment (lacking the
HRE sequence) was generated, as described previously. [11] Using
this plasmid, we demonstrated that the enhancer isoforms
increased expression in 293T cells, whereas the TEAD4216
isoform retained its ability to inhibit VEGF promoter activity
(Figure 3). The HRE-independent, TEAD4216-mediated repres-
sion of VEGF promoter activity was approximately 50% below
background control levels. The full length TEAD4 requires four
consecutive Sp1 sequences (Sp1–1 to Sp1–4) situated between
2100 and 240 bp upstream of the human VEGF transcription
initiation site to function as an enhancer. [11,12] We show that
TEAD4216 and TEAD4148 can also interact with the Sp1
sequences situated within the VEGF promoter (Figure S3,
Methods S1).
The TEAD4216 Isoform Competitively Inhibits VEGF
Promoter Activity
Cotransfection experiments were performed to test whether the
TEAD4216 isoform competitively inhibited VEGF promoter-
directed transcription in the presence of stimulating isoforms.
Equal copy numbers of TEAD4216 expression plasmid and one
enhancer isoform were co-transfected into 293T cells with a
pSEAP reporter vector under the control of the human VEGF
promoter. The TEAD4216 isoform was able to significantly inhibit
VEGF promoter activity in the presence of stimulatory isoforms
(Figure 4). A dose response trend was observed in experiments that
included the most potent stimulatory isoform (TEAD4148) (Figure
S4). To ensure that expression plasmids containing each of the
TEAD4 isoforms were capable of expressing protein and not
degraded within the time frame of the transfection assays, a
western blot confirmed presence of TEAD4434, TEAD4216 and
TEAD4447 (Figure S5).
The TEAD4216 Isoform Represses VEGF Promoter Activity
Under Hypoxic Conditions
Under hypoxic conditions, HIF-1 subunits bind to the HRE
within the VEGF promoter to enhance gene expression. To test
whether the TEAD4216 isoform represses promoter activity in a
low oxygen environment, 293T cells were co-transfected with the
pSEAP vector containing the human VEGF promoter and an
expression plasmid containing one of each of the TEAD4
isoforms. Transfected cells were then cultured under hypoxic
conditions. The TEAD4216 isoform repressed expression in the
hypoxic environment suggesting inhibitory effect in pathophysio-
logically relevant conditions (Figure 5).
The TEAD4216 Isoform Decreases Native VEGF Production
and Inhibits Cell Proliferation
The 165 amino acid isoform of VEGF (VEGF165) is considered
a key protein in the development of neovascular disease and
neoplasia. [17] To test whether expression of the TEAD4216
isoform inhibits native VEGF production, cells were transfected
with expression plasmids containing the TEAD4216 gene, and
secreted VEGF165 was determined 48 hours following transfection
by ELISA. Relative to the control, the TEAD4216 treated cells
produced less VEGF protein (Figure 6). This reduction in native
VEGF expression was observed in both 293T (Figure 6A) and
retinal pigment epithelial (RPE) cells (Figure 6B). Lentiviral-
mediated expression of the TEAD4216 isoform within RPE cells
similarly reduced VEGF production (Figure 6C). A proliferation
assay was performed to determine whether lentiviral mediated
expression of the TEAD4216 isoform inhibits cell proliferation.
Cells transduced with either a lentiviral vector containing the
TEAD4216 isoform and GFP or GFP alone were FAC sorted and
seeded at equal density into 96 well plates. Cells were cultured for
four days in the presence or absence of serum and subsequently
assayed for cell number. Cells expressing the TEAD4216 isoform
proliferated at reduced rates regardless of the presence of serum
(Figure 7).
Figure 2. The TEAD4216 isoform represses VEGF promoter
activity. The TEAD4216 isoform can repress expression from the full
length human VEGF promoter F1–R3 (p,0.01, n = 9) in contrast to the
TEAD4434 and TEAD4148 enhancers.
doi:10.1371/journal.pone.0031260.g002
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The TEAD4216 Transcription Factor is Localized to the
Cytoplasmic Region
The TEAD4216 isoform lacks the putative nuclear localization
sequence (NLS) situated at the end of the TEA DNA-binding
domain (TEAD) (Figure 1). Enhancer isoforms contain the
complete TEAD and are assumed to function within the nucleus
by binding to cis-elements within chromosomal DNA. In the case
of the VEGF promoter, the full-length TEAD4434 transcription
factor binds to Sp1 elements situated within 100 bp upstream of
the transcriptional start site. [12] To determine the cellular
localization of the TEAD4148, TEAD4216 and TEAD4434 proteins,
fusion constructs of each isoform linked to fluorescent tags were
prepared and expressed within mammalian cells. Fluorescent
imaging demonstrated that the enhancer isoforms were located
within the nucleus whereas the TEAD4216 isoform was present in
the cytoplasm (Figure 8). It would appear that the NLS is essential
for nuclear positioning of TEAD4 isoforms and may determine
whether the protein acts as an enhancer or repressor.
The TEAD4216 Gains Enhancer Activity with a Nuclear
Localization Sequence
In order to dissect which domains within the TEAD4216 isoform
affords repressor activity, mutant and chimeric constructs were
generated (Methods S1) and their effect on the human VEGF
promoter was analyzed (Figure S6). The repressor TEAD4216
containing the complete DNA binding domain including the NLS
sequence (TEAD4216+NLS) enhanced promoter activity whereas
the TEAD4148 without a NLS motif (TEAD4148-NLS) lost the
ability to enhance. A chimeric containing the DNA binding
Figure 3. The TEAD4216 isoform does not require the HRE sequence to function. The TEAD4216 isoform can repress expression from the
human VEGF promoter (F2–R3) that lacks the HRE (p,0.01, n = 6). The TEAD4148 and TEAD4311 enchancer isoforms do not require the HRE to promote
reporter gene expression (p,0.001). However the full length TEAD4434 did not significantly enhance expression (p.0.02).
doi:10.1371/journal.pone.0031260.g003
Figure 4. The TEAD4216 isoform can competitively inhibit
promoter activity. The TEAD4216 isoform can competitively repress
expression from the human VEGF promoter in the presence of either
the TEAD4434 or TEAD4148 enhancer isoforms (p,0.005, n = 6).
doi:10.1371/journal.pone.0031260.g004
Figure 5. The TEAD4216 isoform can inhibit promoter activity
under hypoxic conditions. The TEAD4216 isoform can still repress
expression mediated from the human VEGF promoter (F1–R3) that
includes the HRE sequence under conditions of hypoxia (p,0.001,
n = 6).
doi:10.1371/journal.pone.0031260.g005
The TEAD4216 Isoform Inhibits VEGF Expression
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Figure 6. The TEAD4216 isoform can reduce endogenous VEGF165 protein. Transient plasmid transfection or stable lentiviral mediated
introduction of TEAD4216 into human cells results in reduction of native VEGF protein. Solid bars represent VEGF165 levels, quantified by ELISA, within
conditioned media collected 48 hours after transfection of pcDNA plasmid vector containing the TEAD4216 isoform into (A) 293T cells, (B) ARPE-19
retinal pigment epithelial (RPE) cells in culture (n = 4), (p,0.05). (C) Lentiviral (LV) expression of the TEAD4216 isoform in human D407 RPE cells can
inhibit endogenous VEGF production. Solid bars represent VEGF165 levels, quantified by ELISA, within conditioned media collected 48 hours after
transduced RPE cells were FAC sorted and plated (n = 3),(p,0.02).
doi:10.1371/journal.pone.0031260.g006
Figure 7. Lentiviral (LV) mediated expression of the TEAD4216 isoform in 293T cells inhibits cell proliferation. A Cyquant cell
proliferation assay determining the DNA content of cells indicate that 4 days after initial seeding of equal cell numbers the control untransduced cells
proliferate at a faster rate than the LV-TEAD4216 transduced cells (n = 8, p,0.05).
doi:10.1371/journal.pone.0031260.g007
The TEAD4216 Isoform Inhibits VEGF Expression
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portion of TEAD4216, lacking the NLS, and the non-DNA binding
part of TEAD4148 (59- TEAD4216+39- TEAD4148), as well as the
mutant isoform that consisted of the TEA DNA binding domain
only (DNA BD, containing exons 2 to 4 of TEAD4434) also failed
to enhance. Although, the combination of alternatively spliced
sequences downstream of the complete TEA DNA binding
domain may influence potency of enhancement, as evidenced by
the TEAD4434 and TEAD4216+NLS isoforms, the same sequence
loses enhancer function without a functional NLS (Figure S6).
TEAD4 is Present in Ocular Tissue in Primate Ischemic or
Neovascular Eye Disease
Occlusion of the central retinal artery or vein leads to ocular
hypoxia and often results in a rapid increase of intra-ocular
VEGF. [18,19] Analysis of retinal, choroidal and iris tissue for
TEAD4 RNA in a non-human primate (NHP) model of central
retinal artery occlusion (CRAO) indicated that the TEAD4434
form of TEAD4 was upregulated in the ischemic eye and
undetectable in the contralateral control eye (Figure 9). In
addition, the NHP orthologue of the human TEAD4148 isoform
was found to be present in iris tissue from the ischemic eye and not
in the normal control eye (Figure 9). Sequence comparison of the
human TEAD4148 and NHP TEAD4148 isoforms indicated 98.4%
identity at the nucleotide and 96.6% identity at the protein level.
Choroidal neovascularization is a common sequelae of age-
related macular degeneration and is a VEGF-mediated process.
[20,21] To test whether TEAD4 is present in neovascular
complexes associated with AMD, antibodies raised against human
TEAD4 were used in immunohistopathologic analysis of sections
from eyes with neovascular AMD. Hematoxylin and eosin staining
demonstrated subretinal neovascular membranes in the three
globes obtained post-mortem from three patients with age-related
macular degeneration. Endothelium of choroidal new blood
vessels within the membrane stained positively for TEAD4 in
two eyes (Figure 10); the third eye showed relatively weak staining
overall. In addition and for all eyes, positive extracellular staining
was observed within the membrane. This finding was attributed to
leakage of serum from the abnormal vasculature into the tissue,
since similar staining of serum was also present within vessels.
Subretinal blood stained positively in one eye. In addition to
staining within the neovascular membrane, anti-TEAD4 antibody
recognized some other ocular cells. Positive staining was identified
in retinal pigment epithelium and corneal epithelium, and for one
globe that showed most staining overall, there was also convincing
staining of ciliary epithelium, retinal neurons and endothelium of
Figure 8. The TEAD4148 and TEAD4434 isoforms that enhance VEGF expression are localized to the nucleus whereas the TEAD4216
repressor isoform is maintained in the cytoplasm. TEAD4 isoforms were expressed as fusion proteins within 293T cells with various fluorescent
proteins (FP) (TEAD4434 -Green-FP, and TEAD4148-Yellow-FP (pseudo-colored green) and TEAD4216-Green-FP) to visualize cellular localization.
doi:10.1371/journal.pone.0031260.g008
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some normal vessels in the choroid and pars plana. Tissue sections
stained with rabbit IgG revealed no positive staining.
Discussion
We report the discovery of a novel TEAD4 isoform, isolated
from vascular endothelial cells derived from human eyes, that
represses gene expression from the VEGF promoter. We note that
through alternative splicing of TEAD4 transcripts, different
proteins are synthesized; some of these isoforms act as strong
enhancers of transcription from the VEGF promoter, while others
act as strong repressors.
Vascular endothelial growth factor has been implicated as a key
component responsible for the onset and promotion of neovascu-
larization. VEGF-associated neovascularization is involved in the
pathology of blinding eye diseases such as proliferative diabetic
retinopathy, retinopathy of prematurity (ROP) and AMD. In
addition to ocular disease, solid tumor growth requires abundant
neovascularization to supply nutrients for survival and growth.
Thus, it is not surprising that drugs that inhibit the actions of
VEGF proteins are useful in the treatment of ocular neovascular
disease and neoplasia. [22,23] On the other hand, the protein
factors that control VEGF transcription in health or disease is less
understood; these proteins may also prove to be potential
therapeutic targets.
Under hypoxic conditions, expression of VEGF is upregulated
in a variety of tissues. This hypoxia-mediated stimulation of VEGF
is attributed mainly to the stabilization of the transcription factor
HIF-1 alpha. [13,24] Targeting HIF-1 alpha may be useful in
inhibiting neovascular disease, but as with most biological systems,
alternative mechanisms and pathways provide functional redun-
dancy. Recently, the full length TEAD4 protein (TEAD4434) was
shown to stimulate VEGF gene transcription under hypoxic
Figure 9. TEAD4 is upregulated and alternatively spliced within the eye in an animal model of ocular ischemic disease. RT-PCR for
TEAD4 from choroidal, retinal and iris tissue isolated from a non-human primate eye (Rhesus macaque) 24 hrs after occlusion of the central retinal
artery (CRAO), indicates that the full length TEAD4434 transcript is increased and the TEAD4148 enhancer isoform is produced in the lasered eye. L=
Lasered CRAO eye; C = control eye.
doi:10.1371/journal.pone.0031260.g009
Figure 10. Human TEAD4 protein is present on new vessels in neovascular AMD lesion. Photomicrograph showing a subretinal
neovascular membrane in a human ocular tissue section (Fast Red, TEAD4; hematoxylin counterstain; original magnification x 100). Insert (location
indicated by rectangle; original magnification x 1000) shows positive staining for TEAD4 by vascular endothelium of a choroidal new vessel that has
bridged the elastic lamina of Bruch’s membrane.
doi:10.1371/journal.pone.0031260.g010
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conditions in bovine cells and to act independently of the HIF-1
pathway. From hypoxic ocular endothelial cells, we recently
identified an alternatively spliced TEAD4 transcript able to
encode a new isoform (TEAD4148) that is capable of enhancing
VEGF promoter activity 3 to 5 times greater than that achieved by
the full length TEAD4 protein and 10 times greater than the
control. Whether specific alternatively spliced products of TEAD4
are biologically relevant to VEGF-dependent diseases is unknown.
Nevertheless, disease specific splicing of TEAD4 within the mouse
retina in a model of ROP has been noted. [11] Disease specific
splicing within human tissue of other members of the TEAD
family has also been observed. Whether repressing the transcrip-
tion-enhancing isoforms or employing the transcription-inhibiting
isoforms can help disrupt neovascularization remains to be
determined.
The initial discovery of VEGF as a secreted molecule was
observed in rodent and human tumor cell lines, and the protein
was believed to be a mitogen specific to endothelial cells.[25–28]
Subsequently, VEGF was shown to act as a potent inducer of cell
proliferation, migration or survival in a wide variety of cells not of
endothelial origin, including smooth muscle cells, retinal cells and
neurons, glial cells, pericytes and mammary tumor cells.[29–40]
Inhibition of VEGF production in tumor cells may help in
treatments for cancer. We demonstrate that lentiviral transduction
of TEAD4216 into HEK 293T cells results in an inhibition of
proliferation in both serum-containing and serum-free media as
measured by a cell proliferation assay. The ability of the
TEAD4216 isoform to act as a suppressor of cell division is
intriguing and may prove to be of therapeutic benefit.
We have previously demonstrated that TEAD4 transcripts are
alternatively spliced within the retina of a mouse model of ROP.
[11] We now show that the full length TEAD4434 is upregulated
under ischemic conditions within the primate eye. Interestingly, in
a primate CRAO model, expression of the TEAD4 isoform with
highest stimulatory activity (i.e. TEAD4148) is seen at highest levels
in iris tissue, a site of clinically relevant neovascularization in
humans with vaso-occlusive disease. [41] Neovascularization of
the iris is noted as a consequence of blockage of retinal blood
vessels in primates and VEGF is known to play a significant role.
[42,43] The VEGF receptors, VEGFR1 and VEGFR2, and
VEGF are expressed within primate iris tissue. [44] It is possible
that the TEAD4148 isoform may be produced within the iris under
conditions of ocular hypoxia to initiate the VEGF cascade thereby
stimulating neovascularization. Thus, it would appear that not
only expression, but also alternative splicing of the TEAD4 gene, is
regulated by hypoxia and this mechanism may be tissue and/or
cell specific (Figure S1).
Vascular endothelial growth factor is a key component to the
etiology of AMD and treatments for blocking the action of VEGF
have proven to be standard of care for this disease. [20] We have
shown that human choroidal endothelial cells express TEAD4
transcripts in vitro and that expression is upregulated under
conditions known to stimulate neovascularization. The potential
role of hypoxia in the stimulation of VEGF expression in AMD is
unclear. Here, we demonstrate the presence of TEAD4 protein in
choroidal neovascular complexes in human eyes with neovascular
AMD (Figure 10). Interestingly, HIF is absent from choroidal
endothelial cells in AMD-related neovascular complexes, and thus
a HIF-independent, TEAD4 pathway may regulate VEGF
expression in these cells. [45].
Analysis of the TEAD4216 isoform suggests that it acts as an
inhibitor of transcription of the VEGF gene even in the presence of
stimulatory isoforms (Figure 4). Sequence analysis of the TEAD4216
isoform shows that it lacks a portion of the TEA DNA binding
domain (the third alpha helix which includes a nuclear localization
signal) that is retained by enhancer isoforms. Fusion protein
experiments indicate that the TEAD4216 isoform remains in the
cytoplasm, while the enhancing isoforms are found within the
nucleus; suggesting that the repression effect may occur within the
cytoplasm. It is possible that TEAD4216 mediated inhibition of
VEGF occurs by some other indirect pathway, that involves protein
degradation or regulation of other genes, that maybe cell- and cell-
state specific. [46] Understanding the mechanism of action of this
promoter repressor may lead to the discovery of essential cofactors
that are required for the function of TEAD4. [47,48] How
competitive inhibition is achieved when the enhancer isoforms are
physically located within the nucleus is intriguing and warrants
further investigation. Most recently, specific cofactors that are
essential for TEAD4434 mediated induction of the VEGF gene in
muscle cells and that TEAD4434 may also upregulate the HIF-1
alpha gene via MCAT sequences in endothelial cells have been
noted. [49,50] Whether the other TEAD4 isoforms possess the
ability to effect expression of the HIF-1 alpha gene or require the
same specific cofactors for function and if this is a cell specific
phenomenon needs further study. The full length TEAD4434
interacts with YAP65 to mediate transcription from muscle-specific
genes. [51] Introduction of TEAD4 into cells lacking all TEAD
proteins failed to elicit gene transcription until YAP was coin-
troduced with a TEAD protein. [51] The carboxyl half of the
TEAD4 protein, amino acids 224 to 434, is considered essential for
binding to YAP and more specifically four specific amino acids,
K297, W299, F337 and Y422 are critical for YAP interaction.
[51,52] The amino acids K297 and W299 are within exon 9, F337
is contained in exon 10 while Y422 is in exon 12. Only TEAD4434
contains all 4 of these amino acids, whereas the repressor TEAD4216
possesses F337 and Y422 only, while the potent enhancer
TEAD44148 contains Y422 only (Figure 1). Thus, it is unlikely that
either TEAD4216 or TEAD4148 binds YAP with strong affinity and
may use other cofactors to mediate their function.
Other cofactors such as transcriptional coactivator with PDZ
binding motif (TAZ), interferon response factor 2 binding protein
2 (IRF2BP2), a basic helix-loolp-helix leucine zipper protein
(MAX), and serum response factor (SRF) a member of the MADS
box superfamily of transcription factors have all been implicated as
potential cofactors of TEAD4 and other members of the TEAD
family of proteins. [47,48,50,53] Interestingly, both TAZ and YAP
are involved in the Hippo signaling pathway, an organ growth
control system that involves the regulation of genes responsible for
cell proliferation and apoptosis.[52,54–56] The TAZ protein is a
14-3-3 binding protein and both YAP and TAZ activity are
repressed by the Hippo pathway, by phosphorylation and
sequestering of these proteins to the cytoplasm. Perturbation of
the Hippo pathway has been implicated in cancer and uncon-
trolled cell division. [57] Considering that TEAD is essential for
YAP-mediated cell growth, it is not unreasonable to consider the
possibility that inhibitor TEAD4216 isoform may play a role or be
utilized to regulate the Hippo pathway.
Characterizing the function of the new TEAD4216 isoform may
lead to a better understanding of the control of VEGF gene
regulation and may allow the development of therapeutics to
inhibit VEGF gene transcription, pathologic neovascularization
and cell proliferation through a HIF-independent mechanism.
Materials and Methods
Cultured Cells
Primary human ocular vascular endothelial cells were isolated
from human retinal, iris and choroidal tissue and cultured as
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previously described, in the laboratory of Dr James T. Rosen-
baum. [11] Total RNA was extracted from these cells when they
were 99% pure, as evaluated by morphologic criteria, and at
passages 2 to 5. Human 239T cells and ARPE-19 cells were
purchased from ATCC and cultured in DMEM with 10% FBS, or
serum free, and used for promoter reporter assays. The D407 RPE
cell line (a gift from Dr. R. C. Hunt, University of South Carolina,
Columbia, SC) were cultured in RPMI media with 10% FBS.
Induction of Hypoxia
Cells were cultured in either 6 well or 12 well plates after
transfection with expression and reporter gene plasmids. Cells
were recovered overnight under normoxic conditions, and media
was exchanged before placement in the Modulator Incubator
Chamber (Billups-Rothenberg, Del Mar, CA) for hypoxic gas
flushing. A 1% O2, 5% CO2 and 94% N2 gas mix was flushed
through the chamber for exactly 5 minutes. The chamber was
sealed and placed in a humidified 37˚C incubator. After an 8 hour
incubation, the chamber was flushed again with hypoxic gas for 5
minutes, and resealed and incubated for a further 8 hours. The
flush and reincubation sequence was repeated once more before
total RNA was isolated. Media was collected for reporter protein
analysis 8 hours after the final flush.
RNA Extraction and RT-PCR
Total RNA was isolated using an RNAqueous kit (Ambion Inc,
Austin, TX) and 150 ng of this RNA was used with an oligo-dT
primer for first strand synthesis (SuperScript II, Stratagene, La
Jolla, CA). The following primers, F1: 59-ttggagggcacggccggca-39
and R1: 59-tcattctttcaccagcctgta-39 was used for second strand
PCR amplification of TEAD4 using standard conditions. Ampli-
fied products were electrophoresed and visualized on a 1.5%
agarose gel and subsequently purified from the gel (Qiaquick Gel
Extraction, Qiagen, Valencia, CA) for standard dideoxynucleotide
sequencing on an ABI 310 automated sequencer.
Reporter Gene Analysis
The cDNA for TEAD4 isoforms were directionally cloned into
the pcDNA 3.1 expression plasmid (Invitrogen, Carlsbad, CA).
Human VEGF 59 proximal promoter fragment (F1–R3) of
1,136 bp containing 54 bp of 5 UTR and 1,082 bp upstream of
the transcription start site (TSS) was cloned 59 to the secretable
alkaline phosphatase (SEAP) gene within the pSEAP reporter
plasmid (Clontech, Mountain View, CA). Truncated VEGF
promoter fragment (F2–R3), which lacked the HRE sequence,
containing 580 bp sequence 59 to the TSS, was generated by
nested amplification from the F1–R3 clone. The F2–R3 fragment
was directionally cloned into the promoterless pSEAP vector. All
constructs were sequence confirmed on both strands prior to
transfection studies.
Transfection Assays
The Amaxa Nucleofection Device (Amaxa Inc, Gaithersburg,
MD), with Amaxa reagents and standard manufacturer’s protocol,
was used to transfect plasmid vectors into cells. Briefly, 293T cells
were cultured until 80% confluent and subsequently trypsinized.
One million cells were resuspended in 100 ml of Nucleofect
solution, mixed with 5 ml (containing 2 mg) of total plasmid DNA,
and then electroporated (program #A023). Nucleofected cells
were immediately resuspended in pre-warmed media and seeded
into single wells of a 6 or 12-well plate. Cells were recovered
overnight, before media was replaced with exactly 500 ml of fresh
media. After 6 to 24 hours incubation, 200 ml of media was
carefully removed and 25 ml of this was assayed immediately or
stored at 220uC for SEAP analysis. Two separate 25 ml media
aliquots were used for SEAP analysis according to manufacturer’s
protocol (BD Biosciences, San Jose, CA). The two readings from
one well were averaged for comparison to triplicate/quadruplicate
repeat wells. Each co-transfection was repeated in triplicate or
quadruplicate for a single experiment. Each experiment was
repeated independently two more times with separate plasmid
preparations (n = 9–12). A representative experiment is presented.
Statistical analysis was performed using a Student’s t-test (two-
tailed) to compare the triplicate samples in a single experiment.
Bonferroni correction for multiple testing was applied and a
P,0.01 was considered as significant.
For each co-transfection, the copy number of each plasmid was
adjusted to be equivalent to the copy number of the largest
plasmid used. The pcDNA 3.1 expression plasmid with no insert
served as a control. As positive controls, a SV40 promoter pSEAP
plasmid and a pGFPmax vector were transfected to ensure
efficient and equal transfection efficiencies. The pSEAP plasmid
with an SV40 promoter served as a positive control for subsequent
SEAP protein analysis. The pGFPmax vector also served as
positive control for transfection for each batch of cells allowing
visual confirmation of consistent transfection efficiency. Nucleo-
fection consistently gave 75–90% transfection efficiency in all
experiments.
Quantification of Secreted VEGF Protein
The level of VEGF165 protein was quantified using a standard
ELISA kit (Chemicon, Temecula, CA), according to the manu-
facturer’s protocol. Cells were Nucleofected as described above
with either 2 mg of pcDNA vector containing the cDNA for
TEAD4216 or an equal copy number of the vector with no insert as
a control. Cells were recovered overnight, and the media was
replaced. The conditioned media was collected 24 hrs later and
2650 ml of media was collected from each well (n = 4) for use in
the ELISA.
Laser Induced Central Retinal Artery Occlusion (CRAO)
All animal experiments were approved by the Institutional
Animal Care and Use Committee and handled in accordance with
the ARVO statement for the Use of Animals in Ophthalmic and
Vision Research. Retinal artery occlusion was induced in the right
eye of a cynomolgus primate via Rose bengal-assisted laser
occlusion technique (532 nm laser); the left eye served as a control.
Color photographs and fluorescein angiography (FA) were taken
immediately after the procedure to confirm occlusion after the
CRAO was induced. Briefly, cynomolgus primates (Macaca
fascicularis, Sierra Biomedical Inc., Whitmore CA) were anesthe-
tized by intramuscular injection of a mixture containing ketamine
hydrochloride (20 mg/ml) and acepromazine maleate (0.125 mg/
ml). Pupils were dilated (1% Cyclogel, 2.5% Phenylepherine, 0.5%
Tropicamide). Eyes were topically sterilized and proparacaine
hydrochloride was used as topical anesthesia. Immediately after
Rose Bengal (Sigma, St. Louis, Mo, 20 mg/ml in normal saline)
was injected into the femoral vein (20 mg/kg), the central retinal
artery was irradiated with a 532 nm argon green laser (Iridex Inc.,
Mountain View, CA) via a stabilized slit-lamp delivery system.
Following color photography (Ziess, fundus camera), 0.5 ml of
fluorescein was injected and FA was performed to confirm
occlusion of the central retinal artery. Retinal, choroidal, and iris
tissue were harvested 24 hours after occlusion, and RNA was
obtained. Total RNA was isolated from the three tissue groups
(Ambion), quantified and followed by semi-quantitative RT-PCR
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for the TEAD4 transcript. The GAPDH housekeeping gene
served as the loading control.
Cell Proliferation Assay
Cell proliferation was determined using a standard assay
(CyQuant NF Cell Proliferation Assay Kit, Molecular Probes,
Eugene OR). The TEAD4216 cDNA insert was cloned into the
pLenti7.3 vector (Invitrogen, Carlsbad, CA) and lentivirus (LV-
TEAD4216) was prepared according to the manufacturer’s
protocol. The LV-TEAD4216 virus was used to transduce 293T
cells in wells of a 6-well plate, and transduced cells were FAC
sorted using the emerald GFP encoded by the vector. LV-GFP was
used as a control. LV-TEAD4216 positive cells were seeded at 10
5
cells in 80 ml of media into each well of a 96-well culture plate
(N = 8). Cells were incubated for 3 to 4 days at 37uC with 5% CO2
in a humidified chamber. Media was carefully aspirated from wells
without disturbing the cells. Exactly 50 ml of Cyquant NF staining
solution was added to each well, and wells were incubated at 37uC
with 5% CO2 for 30 min to 1 hour. The plate was read in a
Victor3 plate reader (Perkin Elmer, Waltham, MA). Statistical
significance was determined by a paired Student’s t-test. Each
experiment was performed in octuplicate and each proliferation
assay was performed at least twice.
Immunostaining of Eyes with Neovascular AMD
Three globes from 3 patients diagnosed with AMD were
obtained post-mortem, fixed in 10% neutral buffered formalin and
embedded in paraffin; these individuals were aged 77, 80 and 85
years at time of death. The Oregon Health & Science University
Institutional Review Board provided a determination that this
study did not constitute human subjects research. Ocular cross-
sections were cut 5 microns thick, and mounted on Superfrost Plus
glass slides (Fisher Scientific, Pittsburgh, PA) and heated overnight
at 37uC, followed by 1 hour at 60uC, to promote firm adhesion.
TEAD4 was visualized in tissue sections, according to a
previously published indirect immunostaining method [58], using
rabbit polyclonal anti-TEAD4 antibody (made to order by
Genemed Synthesis, San Antonio, TX, see Methods S1 for details
of custom made antibody) or, as negative control, rabbit IgG
(Vector Laboratories, Burlingame, CA), at a concentration of
11 ug/mL. Antigen retrieval was performed by immersing the
slides in 10 mM citrate buffer (pH 6.0) and boiling for 10 minutes
in a microwave oven. To visualize antibody complexes, sections
were incubated with Fast Red (Biogenex, San Ramon, CA), as
described by the manufacturer. Subsequently the sections were
counterstained with hematoxylin. Immunostaining was interpreted
by comparison with hematoxylin and eosin-stained sections.
Supporting Information
Figure S1 Human TEAD4 is differentially spliced within
retinal, choroidal and iris derived vascular endothelial
cells under hypoxia/normoxia. Agarose gel electrophoresis
showing RT-PCR from RNA isolated from primary cultures of
REC, CEC and IECs after culture under normoxic or hypoxic
conditions. Donor #1 (pooled REC, CEC and IEC cells) gave
products for TEAD4434 (1305 bp band), TEAD4311 (936 bp
band), TEAD4216 (651 bp band) and TEAD4148 (447 bp band)
under hypoxic conditions, and under normoxic conditions only the
TEAD4216 product was amplified. TEAD4216 was present in
REC, CEC and IEC but interestingly expression levels differed
between each EC type and between normoxic and hypoxic
conditions.
(TIF)
Figure S2 Western blot for TEAD4 on nonhuman
primate ocular vascular endothelial cell proteins recog-
nizes TEAD4434 and other isoforms. Two different com-
mercially available antibodies (ARP33426 and ARP38276, Aviva)
recognize the full length TEAD4 (,50 kD) in monkey retinal-
choroidal ECs (RF/6A). No significant difference in TEAD4
expression was observed when normoxic (N) samples were
compared to hypoxia (H) treated samples. Other TEAD4 isoforms
appear to also be recognized at 30 KD, 26 kD and 24 kD.
(TIF)
Figure S3 Band shift (EMSA) assay for TEAD4 isoforms
on Sp-I sequences found within the VEGF promoter. The
enhancer isoforms TEAD4434, TEAD4216 and TEAD4148 bound
to the SpI sequences present within the human VEGF promoter.
The repressor isoform TEAD4216, although lacking one of the 3
helixes present within the TEA DNA binding domain, is still able
to bind the Sp-I sequences within the VEGF promoter.
(TIF)
Figure S4 TEAD4216 can competitively inhibit enhancer
mediated VEGF promoter activity. Increasing concentra-
tions of a plasmid containing TEAD4216, inhibited the enhancer
properties of TEAD4148.
(TIF)
Figure S5 Expressed protein from transfected TEAD4
isoforms is stable over time. Protein from cells was isolated at
various time points (24 to 96 hours) after transfection with pcDNA
expression vector containing a TEAD4 isoform. Western blot was
performed with a custom made TEAD4 antibody (Genemed
Synthesis).
(TIF)
Figure S6 TEAD4216 requires an NLS to enhance VEGF
promoter activity. A reporter assay using the full length human
VEGF promoter F1–R3 and chimeric TEAD4 isoforms,
TEAD4216 with a NLS and TEAD4148 without an NLS showed
that the NLS domain was crucial for enhancers to function and
that loss of the NLS converts a potent enhancer (TEAD4148) into
an inhibitor. The chimeric TEAD4216+NLS isoform significantly
enhanced promoter activity (p,0.01, n = 3).
(TIF)
Methods S1 A description of electrophoretic mobility
shift assays, culture of RF/6A cells, antibodies used and
TEAD4 chimeric constructs.
(DOC)
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